Press releases
- Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
- Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
- Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
- Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
- Mahesh Krishnan Elected to Halozyme's Board of Directors
More ▼
Key statistics
On Monday, Halozyme Therapeutics Inc (RV7:DUS) closed at 49.46, -1.83% below its 52-week high of 50.38, set on Jul 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 49.46 |
---|---|
High | 49.46 |
Low | 49.46 |
Bid | 49.84 |
Offer | 49.99 |
Previous close | 49.69 |
Average volume | 68.10 |
---|---|
Shares outstanding | 127.27m |
Free float | 125.86m |
P/E (TTM) | 22.65 |
Market cap | 6.97bn USD |
EPS (TTM) | 2.42 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 07:11 BST.
More ▼